clinical trials thailand

Stem Cells Clinical Trial Updates and Outcomes – 2023

Stem cell treatments and clinical trials have been going on for over 40 years, however we are still in the early stages of stem cell therapy being utilized as an effective alternative treatment method to traditional pharmaceutical based treatments. Much of the early work in stem cell clinical trials focused on the overall effectiveness and safety of the procedures involved. The primary concern with any new treatment are the long term safety and standardization of results. There has been countless journals and research papers focusing in on these clinical trials that have revealed promising results from these initial trials around the world

Here are some resources for clinical trials using stem cells around the world.

Open Stem Cell Trials – Currently Accepting New Patients


Closed or Completed Stem Cell Trials – Results (Primarily in the United States unless noted otherwise)

  • ALS and MND Stem Cell Trials at Emory University
  • Clinical applications of mesenchymal stem cells
  • Autologous stem cell transplantation in adults with acute lymphoblastic leukemia
  • In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells.– Multipotent cells isolated from human term placenta (placenta-derived multipotent cells [PDMCs]) have been known to be able to differentiate into mesodermal lineage cells, including adipocytes and osteoclasts. The low infection rate and young age of placenta compared with other tissue origins of adult stem cells make theses cells attractive target for cell-based therapy.
  • Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Bone marrow is the traditional source of human multipotent mesenchymal stem cells (MSCs), but placenta appears to be an alternative and more readily available source. This study comprehensively compared human placenta-derived MSC (hpMSC) and human bone marrow-derived MSC (hbmMSC) in terms of cell characteristics, optimal growth conditions and in vivo safety specifically to determine if hpMSC could represent a source of human MSC for clinical trial. MSC were isolated from human placenta (hpMSC) and human bone marrow (hbmMSC) and expanded ex vivo using good manufacturing practice-compliant reagents
  • The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT) – The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium; often a hostile environment of limited blood supply and immunorejection.
  • Australian Clinical Trials  – Therapy for Peripheral Vascular Disease – Double blind, randomized safety and feasibility evaluation of intra-arterial CD34+ cell delivery for severe peripheral arterial disease – This trial in Australia aims to compare the effect of the patient’s own peripheral blood stem in treating patients with severe peripheral arterial disease. The trial is being conducted at the Alfred Hospital in Melbourne and proposes to recruit 20 subjects. The subjects will be randomly assigned to two groups. They will either receive a single injection of CD 34+ stem cells via the limb artery (experimental group) or a placebo injection (control group). Participants will be monitored for complications and assessed for changes in their clinical condition